Phaseline

Targets › PERV

PERV: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Genitourinary; next expected readout Oct 2028.

Open in Phaseline: the race on PERV, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
United Therapeutics10 GE Xenokidney
Porcine-derived kidney with intentional genomic alterations (knockout of GGTA1, CMAH, BHMT
GGTA1, CMAH, BHMT, PERVPhase 1ESRD (End-Stage Renal Disease)Oct 2028

Conditions

ESRD (End-Stage Renal Disease) (1)

Modalities

protein or peptide (1)

Companies

United Therapeutics (1)

Related targets

GGTA1 (1) CMAH (1) BHMT (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.